City Therapeutics (CTY) Financials: Revenue & Earnings

CTY price $21.41 +0.55 +2.63%

Ticker
CTY
Price
$21.41
Change
+0.55 +2.63%
Market cap ?
$208.13M
Sector
Healthcare
Industry
Biotechnology

Fair value

CTY fair value $2,160.27. Price $21.41. Price is 99% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 2.17B. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 10.00%. Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 9.72M. Net debt 5.95B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Model uncertainty high for this stock

Compare CTY

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
No data yet.

Dividends

Yield 0.00%. Payout ratio 87.58%. Frequency —.

Safety score 19/100 · At risk. Payout ratio is 88% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
No data yet.

Institutional holders

HolderSharesChangeChange %Value
No data yet.

Earnings and financials

City Therapeutics Inc. (CTY) trades at $21.41, with a market cap of $208.13M and a trailing P/E of n/a. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

City Therapeutics (CTY) Financials: Revenue & Earnings

CTY$21.41+0.55 +2.63%

$208.13M

Market Cap

—

P/E

—

Forward P/E

—

Score

Price History